MFS
GALT icon

MSI Financial Services’s Galectin Therapeutics GALT Stock Holding History

MSI Financial Services’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-4,194
Closed -$5K – 3877
2016
Q3 		$5K Buy
+4,194
New +$7.46K ﹤0.01% 3127

Other funds holding GALT

DADC
D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return
BCA
Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return
CCM
Courage Capital Management Nashville, Tennessee $70.6M AUM 13.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

MSI Financial Services's GALT Position: Q4 2016 in Review

MSI Financial Services sold out of Galectin Therapeutics (GALT) in Q4 2016, closing a stake of 4,194 shares — an estimated $5K sold.

MSI Financial Services first reported a position in GALT in Q3 2016 and held it in 1 quarter. The position peaked at $5K in Q3 2016. 43 funds tracked by Wall St. Rank hold GALT as of Q4 2016.

  • MSI Financial Services reported no remaining Galectin Therapeutics position as of Q4 2016 after selling out during the quarter.
  • MSI Financial Services sold 4,194 Galectin Therapeutics shares in Q4 2016, an estimated $5K.
  • MSI Financial Services first reported a position in Galectin Therapeutics in Q3 2016 and held it in 1 quarter.
  • MSI Financial Services's Galectin Therapeutics position peaked at $5K in Q3 2016.
  • 43 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q4 2016.

Based on MSI Financial Services's 13F filing for Q4 2016, filed 13 Jan 2017.